SLC5A2 and hydrops fetalis: The strength of these results was that the majority of the patients included in the study received conventional HF therapies, including SGLT2 inhibitors, so that these findings may open perspectives for predicting treatment response in HF patients with T2DM with any levels of NT-proBNP.